Although loaded with contradictions, biopharmaceutical-based socially responsible investing is picking up pace in the market
Dec 1, 2007
By:
Brian O'Connell
More than $1 out of every $9 under professional management in the United States is involved in socially responsible investing.
|
The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008
Nov 1, 2007
By:
Brian O'Connell
The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008
|
At a time when liquidity is difficult to come by, biopharmaceutical firms will find it difficult to find the capital they need to keep going
Sep 1, 2007
By:
Brian O'Connell
Closer examination shows there's a strong bond between the biotech market and the unraveling credit markets.
|
While small caps are more volatile than their large-cap brethren, they offer benefits galore to investors of all stripes
Aug 1, 2007
By:
Brian O'Connell
When you start out, keep your small-cap exposure to no more than 10% of your holdings, and gradually increase.
|
Biotech doesn't play by the same rules that most industries do when it comes to stock performance
Jul 1, 2007
By:
Brian O'Connell
We're seeing an uptick in biotech investing from the venture capital community, a good sign that biotech can rise even higher than the broader markets.
|
Strong valuations, impressive new drug development pipelines, and solid balance sheets project a major long-term buying opportunity in healthcare
Apr 1, 2007
By:
Brian O'Connell
Investors should also scour the landscape and think creatively when investing in healthcare this year.
|
A "pay-for-hay" performance culture is embedded in the industry's DNA.
Feb 1, 2007
By:
Brian O'Connell
In the September 2006 issue I wrote about the ticklish issue of CEO pay and how shareholder groups, especially the powerful pension and other institutional groups, are growing sick and tired of CEO overpayment and underperformance.
|
Biopharm ETFs are popping up everywhere, offering investors the opportunity to climb on the backs of companies fighting disease
Jan 1, 2007
By:
Brian O'Connell
On a recent plane ride from Phoenix to Philly, I was leafing through a copy of the San Francisco Business Journal. I was taken aback by a story on the emerging trend of biopharm exchange-traded funds (ETFs), and how much of an impact they're having on Wall Street and on investors.
|
Adult stem cells are operating under the radar a bit, but are way ahead of their embryonic offshoots in effective products on the market.
Dec 1, 2006
By:
Brian O'Connell
There are 72 maladies for which human patients have received some benefit from adult stem cell interventions.
|
|
